Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Issues of safety and pharmacoeconomics in the treatment of chronic pain in the back and limbs

Full Text:


Nonsteroidal anti-inflammatory drugs (NSAIDs), the long-term administration of which is associated with a risk for complications, gastrointestinal tract (GIT) ones in particular, are extensively used to treat chronic pain in the back and limbs. The paper reviews the data available in the literature on adverse reactions occurring with the use of NSAIDs, discusses the issues of pharmacoeconomics in the administration of various NSAIDs. The use of the selective cyclooxygenase-2 inhibitor meloxicam (Movalis) is noted to cause fewer GIT adverse reactions than that of standard NSAIDs, the cost of treatment for GIT complications reduces.

About the Authors

V. A. Parfenov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Department of Nervous Diseases, Therapeutic Faculty

O. N. Gerasimova
Polyclinic Six, ZAO Medical Services
Russian Federation


1. <div><p>Elliott A.M., Smith B.H., Penny K.L. et al. The epidemiology of chronic pain in the community. Lancet 1999;354:1248-52.</p><p>Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology (Oxford) 2002;41(Suppl.1):7-15.</p><p>Emery P. Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand J Rheumatol 1996;105(Suppl.):5-12.</p><p>Antonov K.I.M., Isacson D.G.L. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacoter 1998;32:485-94.</p><p>Blower A.L., Brooks A., Fenn G.C. et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.</p><p>Moore N., Verschuren X., Montout C. et al. Excess costs related to non-steroidal antiinflammatory drug utilization in general practice. Therapie 2000;55:133-6.</p><p>Cockel R. NSAIDs - should every prescription carry a government health warning? Gut 1987;28:515-8.</p><p>Fries J.F. NSAID gastropathy: the second most deadly theumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;28(Suppl.):6-10.</p><p>Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life treatening complications of peptic ulceration. Gut 1987;28:527-32.</p><p>Steinfeld S., Bjorke P.A. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. Rheumatology (Oxford) 2002;41(Suppl.1):23-7.</p><p>Tramer M.R., Moore R.A., Reynolds D.J.M. et al. Qualitative estimation of rare adverse events which follow a biological pregression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.</p><p>Singh G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. Am J Med 1998;105:31S-38S.</p><p>Moore R.A., Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999;156:2321-32.</p><p>Moore R.A., Phillips C.J., Pellissier J.M. et al. Health economics comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 2001;4:1-17.</p><p>Rahme E., Joseph L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen. Arthr Rheum 2000;43:917-24.</p><p>de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992;96(Suppl.):49-53.</p><p>Knill-Jones R.P. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary of article by G. de Pouvourville. Scand J Rheumatol 1992;96(Suppl.):59-62.</p><p>Rahme E., Joseph L., Kong S.X. et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52:185-92.</p><p>Hurley J., Mucha L., Straus W. et al. NSAID and concomitant gastrointestinal drug use among cases and controls in a managed care population. Gastroenterology 2000;118(Suppl.):A3914.</p><p>Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p><p>Cohen Y., Freeman N.L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs: analysis of a population cohort in Israel. The 14th EULAR Congress. Prague, 13-16 June, 2001.</p><p>Kephart G., Sketris I., Smith M. et al. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior population. Clin Ther 1995;17:1159-73.</p><p>Hogan D.B., Campbell N.R. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994;151:315-22.</p><p>Singh G., Ramey D.R. Gastrointestinal tract complications on non-steroidal anti-inflammatory dryg treatment in rheumatoid arthritis. Arch Inern Med 1996;156:1530-6.</p><p>Moore N., Montout C. Use of gastrointestinal protective agents among patients on nonsteroidal anti-inflammatory drugs in France and prevention of treqtment of adverse GI effects. 12th EULAR Congress. Glasgow, 6-11 June, 1999.</p><p>Caputi A.P., Kong S.X. Concomitant use of gastroprotective agents among users of nonsteroidal anti-inflammatory drugs in Italy. The 14th EULAR Congress. Prague, 13-16 June, 2001.</p><p>Kawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Brit J Rheumatol 1998;37(9):937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Brit J Rheumatol 1998;37(9):946-51.</p><p>Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008;12:11.</p><p>Jansen R.B., Capri S., Nuijten M.J.C. Economic evaluation of meloxicam (7,5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. Brit J Med Econom 1997;11:9-22.</p><p>Tavakoli M. Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam. Pharmacoeconomics 2003;21(6):443-54.</p><p>Насонова В.А., Воробьев П.А., Цветкова Е.С. и др. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. Науч-практич ревматол 2002;1:63-8.</p></div><br />


For citations:

Parfenov V.A., Gerasimova O.N. Issues of safety and pharmacoeconomics in the treatment of chronic pain in the back and limbs. Neurology, Neuropsychiatry, Psychosomatics. 2011;3(2):89-93. (In Russ.)

Views: 654

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)